Transforming Cancer Monitoring
At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.
Oncobit announces partnership with Immunocore to advance therapy response analysis in clinical trials
We are thrilled to announce that we have signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable and real time therapy response marker in clinical trials.
Exciting collaboration with the National Cancer Institute and Klaipeda University Hospital in Lithuania for the BIOMELKID study.
We are delighted to announce that Oncobit is collaborating with the National Cancer Institute (NCI) on the BIOMELKID trial. Our joint mission: To identify predictive and prognostic biomarkers in metastatic melanoma patients undergoing immunotherapy. Professor Vincas Urbonas and his team at the NCI are leading this impactful project focused on the study of ctDNA in melanoma patients. With our Oncobit PM digital PCR solutions, we are pleased to provide a powerful tool to reliably quantify ctDNA. Our shared goal is to unlock the secrets of circulating tumor DNA to better understand disease progression and treatment response. Aiming to improve patient care!
Oncobit among the top 3 finalists for the Swiss Excellence Product Awards 2023
Each year, the Swiss Excellence Foundation honors a Swiss start-up with the Swiss Excellence Award 2023 for an innovative product. The products are judged on their innovative content, their value creation potential and the quality of their business model and marketing concept. Oncobit is pleased to have made it to the finalists and congratulates Perovskia Solar AG for winning the award for its revolutionary and adaptable solar cells.
Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.
Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich